Evidence map›Paper›PMID 37776519›Full record

ArticleCell reports2023

Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15.

Priyadharshini Devarajan, Allen M Vong, Catherine H Castonguay, Noah J Silverstein, Olivia Kugler-Umana, Bianca L Bautista, Karen A Kelly, Jeremy Luban, Susan L Swain

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Priyadharshini DevarajanDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, USA. Electronic address: priyadharshini.devarajan@umassmed.edu.
Allen M VongDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Catherine H CastonguayDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Noah J SilversteinProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Olivia Kugler-UmanaDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Bianca L BautistaDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Karen A KellyDepartment of Animal Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Jeremy LubanProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Susan L SwainDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, USA. Electronic address: susan.swain@umassmed.edu.
University of Massachusetts Chan Medical School · US

Funding

The HUSH complex in HIV-1 latencyR37AI147868 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI JEREMY LUBAN · 2019 to 2026
$6.4M
TRAINING IN IMMUNOLOGY (COMPETITIVE RENEWAL OF AI07439)T32AI007349 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J. · 1989 to 2024
$4.5M
Defining a memory checkpoint for CD4 T cellsR01AI118820 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2015 to 2019
$2.1M
Training in the Molecular Basis of Autoimmunity and AutoinflammationT32AI132152 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Katherine A. Fitzgerald, Ann Marshak-Rothstein · 2018 to 2026
$1.6M
Impact of TcR Signal Strength at the Effector Checkpoint on Protective CD4 T Cell Immunity to Influenza VirusR21AI153120 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2020 to 2021
$461k
Age-Associated B Cells Specialized for Immunity to Pathogens?R21AG068313 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2021 to 2022
$461k
Maintaining Robust T Cell Immunity For Broad Protection Against InfluenzaR21AI146532 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2019 to 2020
$461k
Harnessing Age-Associated B cells for a Universal Influenza Vaccine for the AgedR21AI173593 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2023 to 2024
$461k
Mechanism of epigenetic inheritance in a mouse model of acute paternal stressF30HD100110 · NICHD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SILVERSTEIN, NOAH JACOB · 2019 to 2022
$135k
NIAID NIH HHS R01 AI118820NIAID NIH HHS R21 AI146532NIAID NIH HHS R21 AI153120NIAID NIH HHS R21 AI173593NIAID NIH HHS R37 AI147868NIAID NIH HHS T32 AI007349NIAID NIH HHS T32 AI132152NIA NIH HHS R21 AG068313NICHD NIH HHS F30 HD100110
6 · The paper itself

Abstract

Cytotoxic CD4 T cell effectors (ThCTLs) kill virus-infected major histocompatibility complex (MHC) class II

Indexed as

Antineoplastic AgentsInterferon Type IAntigensCD4-Positive T-LymphocytesHistocompatibility Antigens Class IIInterleukin-15T-Lymphocytes, CytotoxicAntigensAntineoplastic AgentsHistocompatibility Antigens Class IIInterferon Type IInterleukin-15CD4 CTLCD4 cytotoxic T cellsCD4 T cellsCP: Immunologycytotoxic CD4cytotoxic helpercytotoxicityhelper T cellsspecialized CD4tissue-resident effectorsviral infection

Identifiers

PMID37776519
PMCPMC10842051
OpenAlexW4387199981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.